Payment overview · 2025
General Payments
$795.95
36 reported records · 7 companies
Healthcare provider profile · identity verified
John Gray Wallace, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KOSCIUSKO, MS · NPI 1831486596
Verified facts
What the public records show
CMS Open Payments records show John Gray Wallace, M.D. received $795.95 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Nurtec Odt, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 288 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $334.47 | 42.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $180.16 | 22.6% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $105.55 | 13.3% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.79 | 8.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.27 | 7.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.60 | 3.8% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $23.11 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $795.95 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $196.44 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $196.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.16 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.98 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.33 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.09 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $57.27 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.03 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 288 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 89 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 27 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
288 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 692 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 610 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 532 | 122 |
| Meloxicam | Meloxicam | 465 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 447 | 104 |
| Omeprazole | Omeprazole | 436 | 98 |
| Gabapentin | Gabapentin | 419 | 108 |
| Losartan Potassium | Losartan Potassium | 392 | 100 |
| Furosemide | Furosemide | 377 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 350 | 92 |
| Potassium Chloride | Potassium Chloride | 341 | 69 |
| Metformin Hcl | Metformin Hcl | 332 | 84 |
| Eliquis | Apixaban | 288 | 44 |
| Lisinopril | Lisinopril | 285 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 76 |
| Montelukast Sodium | Montelukast Sodium | 263 | 58 |
| Celecoxib | Celecoxib | 253 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 242 | 59 |
| Spironolactone | Spironolactone | 223 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 50 |
| Famotidine | Famotidine | 221 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 53 |
| Carvedilol | Carvedilol | 209 | 41 |
| Chlorthalidone | Chlorthalidone | 206 | 46 |
| Allopurinol | Allopurinol | 199 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 178 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 32 |
| Tramadol Hcl | Tramadol Hcl | 171 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 37 |
| Trazodone Hcl | Trazodone Hcl | 156 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 27 |
| Simvastatin | Simvastatin | 147 | 31 |
| Pregabalin | Pregabalin | 144 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 38 |
| Donepezil Hcl | Donepezil Hcl | 139 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 134 | 79 |
| Prednisone | Prednisone | 127 | 65 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 22 |
| Sertraline Hcl | Sertraline Hcl | 126 | 30 |
| Ozempic | Semaglutide | 121 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 20 |
| Mupirocin | Mupirocin | 117 | 71 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 20 |
| Memantine Hcl | Memantine Hcl | 105 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 101 | 19 |
| Metformin Hcl Er | Metformin Hcl | 96 | 25 |
| Alprazolam | Alprazolam | 94 | 17 |
| Levofloxacin | Levofloxacin | 92 | 65 |
| Linzess | Linaclotide | 89 | 20 |
| Fluconazole | Fluconazole | 86 | 50 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 85 | 16 |
| Azithromycin | Azithromycin | 83 | 69 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 32 |
| Synthroid | Levothyroxine Sodium | 80 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 79 | 12 |
| Trulicity | Dulaglutide | 77 | 11 |
| Meclizine Hcl | Meclizine Hcl | 76 | 19 |
| Methocarbamol | Methocarbamol | 76 | 35 |
| Sucralfate | Sucralfate | 76 | 20 |
| Glipizide | Glipizide | 74 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 42 |
| Xarelto | Rivaroxaban | 73 | suppressed |
| Myrbetriq | Mirabegron | 71 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 34 |
| Alendronate Sodium | Alendronate Sodium | 67 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 64 | 18 |
| Farxiga | Dapagliflozin Propanediol | 64 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 22 |
| Atenolol | Atenolol | 62 | 12 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 13 |
| Mirtazapine | Mirtazapine | 59 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Finasteride | Finasteride | 55 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 14 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 53 | 12 |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Valsartan | Valsartan | 52 | suppressed |
| Cefdinir | Cefdinir | 51 | 45 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Methylprednisolone | Methylprednisolone | 50 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 12 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Dutasteride | Dutasteride | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 29 |
| Novolog Flexpen | Insulin Aspart | 45 | suppressed |
| Olanzapine | Olanzapine | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Nystatin | Nystatin | 36 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 35 | 22 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 29 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | suppressed |
| Savella | Milnacipran Hcl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Prolia | Denosumab | 32 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Colchicine | Colchicine | 27 | 16 |
| Metronidazole | Metronidazole | 27 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 11 |
| Topiramate | Topiramate | 21 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 13 |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tymlos | Abaloparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $795.95 · 36 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Andembry, BREZTRI, COMIRNATY, CREON, ELIQUIS, FARXIGA, LINZESS, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error